Servier Pharmaceuticals shared a post on LinkedIn:
“We’re proud to share that our medicine for patients with Grade 2 IDH-mutant glioma is now approved in the European Union.
We’re grateful to the researchers, patients and advocates who have helped expand our understanding of IDH inhibition and bring this long-awaited breakthrough to patients in the EU.
Read the full announcement here.”
More from Servier Pharmaceuticals on OncoDaily.